194 results on '"Dickler M"'
Search Results
2. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
3. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
4. Interhemispheric inhibition in human wrist muscles
5. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer
6. Clinical Significance of Circulating Tumor Cells in Hormone Receptor���positive Metastatic Breast Cancer Patients who Received Letrozole with or without Bevacizumab
7. SEXUAL DYSFUNCTION IN WOMEN WITH BREAST CANCER: PREVALENCE AND SEVERITY: #30
8. PRELIMINARY DATA—A SURVEY OF FEMALE CANCER PATIENTSʼ PREFERENCE FOR SEXUAL HEALTH INTERVENTIONS: #28
9. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
10. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
11. Increased chemotherapy-induced ovarian reserve loss in women with BRCA mutations: a prospective longitudinal study with mechanistic confirmation
12. 026 Factors Influencing Sexual Function and Its Trajectory Throughout Treatment and Survivorship in Premenopausal Women with Breast Cancer
13. Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies
14. Abstract P6-12-12: Improvement in sexual function over time in premenopausal women with breast cancer
15. Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
16. Abstract P1-09-14: Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up
17. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
18. Abstract ES4-1: Longitudinal strategies in ER+ disease
19. Abstract P4-11-06: Feasibility of a non-hormonal vaginal moisturizer in postmenopausal cancer survivors
20. Menstruation is an unreliable surrogate in the assessment of ovarian damage by chemotherapy: a prospective longitudinal study with AMH levels as the gold standard
21. A prospective longitudinal study of the impact of breast cancer chemotherapy on ovarian reserve: do individuals have differing susceptibilities?
22. The impact of long-term tamoxifen treatment on ovarian reserve markers in women with breast cancer: a prospective-longitudinal study
23. Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer.
24. Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer
25. Abstract P2-12-05: Limited Absorption of Low Dose 10µg Intravaginal 17-β Estradiol (Vagifem®) in Postmenopausal Women with Breast Cancer on Aromatase Inhibitors
26. Germline BRCA1 gene mutations result in accelerated ovarian aging: a translational study
27. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
28. PD04-03: Sexual Dysfunction in Premenopausal Women with Breast Cancer: Prevalence and Severity.
29. P2-08-01: Impact of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue on Breast MRI.
30. PD09-08: Combined Inhibition of mTORC1 with Temsirolimus and HER2 with Neratinib: A Phase I/II Study in Patients with Metastatic HER2−Amplified or Triple-Negative Breast Cancer.
31. PP 66 Utility of VEGF and IL-6 as biomarkers for response to PTC299, a novel antiangiogenic
32. Fertility preservation: Are we telling patients what they want to know?
33. Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study.
34. Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors.
35. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF
36. Abstract P6-12-09: A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC)
37. Abstract P2-16-10: Combination of Tivozanib, an Oral Inhibitor of VEGFR, with Weekly Paclitaxel for Metastatic Breast Cancer: Preliminary Results of an Ongoing Phase 1 Study
38. Abstract P2-16-08: Administration of the Novel Antiangiogenic PTC299 in Combination with Aromatase Inhibitors Is Feasible and Shows Antitumor Activity in Metastatic Breast Cancer
39. Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study.
40. The development and implementation of an institution-based communication skills training program for oncologists.
41. Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC).
42. The novel antiangiogenic, PTC299, as a treatment for women with metastatic breast cancer.
43. Oncology physicians' knowledge, attitudes, and practices regarding fertility preservation.
44. Burden of Sexual Dysfunction in Women with Breast Cancer.
45. Troponins Do Not Predict Cardiotoxicity in a Pilot Study of Adjuvant Bevacizumab (B) Plus Dose-Dense Doxorubicin/Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel (nab-P).
46. Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer
47. Sexual dysfunction in women with breast cancer: Prevalence and severity
48. Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC).
49. Circulating tumor cell and endothelial cell data from a phase II evaluation of lapatinib and bevacizumab in HER2-overexpressing metastatic breast cancer.
50. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.